Immunosuppresion and donor age with respect to severity of HCV recurrence after liver transplantation

Liver Transplantation

Volumn 11, Issue 4, 2005, Pages 386-395

  Samonakis, Dimitrios N ^a   Triantos, Christos K ^a   Thalheimer, Ulrich ^a   Quaglia, Alberto ^a   Leandro, Gioacchino ^a   Teixeira, Rosângela ^a,b   Papatheodoridis, George V ^a,c   Sabin, Caroline A ^a   Rolando, Nancy ^a   Davies, Susan ^a   Dhillon, Amar P ^a   Griffiths, Paul ^a   Emery, Vincent ^a   Patch, Daivd W ^a   Davidson, B R ^a   Rolles, Keith ^a   Burroughs, Andrew K ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c HIPPOKRATION HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; DRUG DERIVATIVE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CADAVER DONOR; CHEMOEMBOLIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; ORGAN DONOR; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RECURRENT INFECTION; SURVIVAL RATE; DRUG COMBINATION; IMMUNOLOGY; MIDDLE AGED; RECURRENT DISEASE; VIROLOGY;

ADULT; AGE FACTORS; AGED; AZATHIOPRINE; CYCLOSPORINE; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRAFT SURVIVAL; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PREDNISOLONE; RECURRENCE; TACROLIMUS;

EID: 20244366386     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1002/lt.20344     Document Type: Article

References (70)

1. Chazouilleres O, Kim M, Combs C, Ferrell L, Bacchetti P, Roberts J, et al. Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology 1994;106:994-999.
2. Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334: 815-820.
3. Gretch DR, Bacchi CE, Corey L, dela Rosa C, Lesniewski RR, Kowdley K, et al. Persistent hepatitis C virus infection after liver transplantation: clinical and virological features. Hepatology 1995;22:1-9.
4. Wright TL, Donegan E, Hsu HH, Ferrell L, Lake JR, Kim M, et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992;103:317-322.
5. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684.
6. Feray C, Caccamo L, Alexander GJ, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. European Concerted Action on Viral Hepatitis (EUROHEP) Group. Gastroenterology 1999;117:619-625.
7. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C virus infection after liver transplantation. Hepatology 1994;20:1137-1143.
8. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002;8(Suppl 1):S19-S27.
9. Gordon FD, Poterucha JJ, Germer J, Zein NN, Batts KP, Gross JB Jr, et al. Relationship between hepatitis C genotype and severity of recurrent hepatitis C after liver transplantation. Transplantation 1997;63:1419-1423.
10. Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl 2003;9:1129-1144.
11. Davis GL. New approaches and therapeutic modalities for the prevention and treatment of recurrent HCV after liver transplantation. Liver Transpl 2003;9:S114-S119.
12. Mueller AR, Platz K, Willimski C, Berg T, Steinmuller T, Neumann U, et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. Transplant Proc 2001;33:1347-1349.
13. Papatheodoridis GV, Patch D, Dusheiko GM, Burroughs AK. The outcome of hepatitis C virus infection after liver transplantation - is it influenced by the type of immunosuppression? J Hepatol 1999;30:731-738.
14. Papatheodoridis GV, Davies S, Dhillon AP, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412-418.
15. Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, et al. Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. Gastroenterology 1999;117:933-941.
16. Patel A, Sodevila-Pico C, Abdelmalek M, Ling Xu Y, Tu Z, Reed A, et al. Defining the role of HCV specific T lymphocytes in hepatitis C recurrence after liver transplantation [abstract]. Gastroenterology 2002;122:A632.
17. Rosen HR, Hinrichs DJ, Gretch DR, Koziel MJ, Chou S, Houghton M, et al. Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999;117:926-932.
18. Schirren CA, Jung M, Worzfeld T, Mamin M, Baretton GB, Gruener NH, et al. Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection. Liver Transpl 2000;6:222-228.
19. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maertens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995;108:1088-1096.
20. Pelletier SJ, Raymond DP, Crabtree TD, Berg CL, Iezzoni JC, Hahn YS, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000;32:418-426.
21. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999;29: 250-256.
22. Zhou S, Terrault NA, Ferrell L, Hahn JA, Lau JY, Simmonds P, et al. Severity of liver disease in liver transplantation recipients with hepatitis C virus infection: relationship to genotype and level of viremia. Hepatology 1996;24:1041-1046.
23. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998;28:823-830.
24. Di Martino V, Brenot C, Samuel D, Saurini F, Paradis V, Reynes M, et al. Influence of liver hepatitis C virus RNA and hepatitis C virus genotype on FAS-mediated apoptosis after liver transplantation for hepatitis C. Transplantation 2000;70:1390-1396.
25. Papatheodoridis GV, Barton SG, Andrew D, Clewley G, Davies S, Dhillon AP, et al. Longitudinal variation in hepatitis C virus (HCV) viraemia and early course of HCV infection after liver transplantation for HCV cirrhosis: the role of different immunosuppressive regimens. Gut 1999;45:427-434.
26. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000;32:1125-1130.
27. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000;6: 553-561.
28. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
29. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
30. Zekry A, Whiting P, Crawford DH, Angus PW, Jeffrey GP, Padbury RT, et al. Liver transplantation for HCV-associated liver cirrhosis: predictors of outcomes in a population with significant genotype 3 and 4 distribution. Liver Transpl 2003;9: 339-347.
31. Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. Hepatology 2003;38:34-41.
32. Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried And MW, Shrestha R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant 2004;4:1133-1138.
33. Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, et al. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation 2004; 77:226-231.
34. O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002;360: 1119-1125.
35. Mela M, Raimondo ML, Quaglia A, Dhillon A, Rolles K, Davidson B, et al. Randomised trial of tacrolimus monotherapy versus tacrolimus/azathioprine/prednisolone for HCV cirrhosis: early rejection rates [abstract]. J Hepatol 2003;38(Suppl 2):44.
36. Rolles K, Davidson BR, Burroughs AK. A pilot study of immunosuppressive monotherapy in liver transplantation: tacrolimus versus microemulsified cyclosporin. Transplantation 1999; 68:1195-1198.
37. Raimondo ML, Dagher L, Papatheodoridis GV, Rolando N, Patch DW, Davidson BR, et al. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation 2003;75:186-190.
38. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
39. Datta GS, Hudson M, Burroughs AK, Morris R, Rolles K, Amlot P, et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 1995;21:46-57.
40. Ormonde DG, de Boer WB, Kierath A, Bell R, Shilkin KB, House AK, et al. Banff schema for grading liver allograft rejection: utility in clinical practice. Liver Transpl Surg 1999;5:261-268.
41. Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology 2000;31:792-799.
42. Stuyver L, Rossau R, Wyseur A, Duhamel M, Vanderborght B, Van Heuverswyn H, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74(Pt 6):1093-1102.
43. Simmonds P, Smith DB, McOmish F, Yap PL, Kolberg J, Urdea MS, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions. J Gen Virol 1994;75(Pt 5):1053-1061.
44. Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993;31:882-886.
45. Adam R, Cailliez V, Majno P, Karam V, McMaster P, Caine RY, et al. Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. Lancet 2000; 356:621-627.
46. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699.
47. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
48. Burak KW, Kremers WK, Batts KP, Wiesner RH, Rosen CB, Razonable RR, et al. Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C. Liver Transpl 2002;8:362-369.
49. Cescon M, Grazi GL, Ercolani G, Nardo B, Ravaioli M, Gardini A, et al. Long-term survival of recipients of liver grafts from donors older than 80 years: is it achievable? Liver Transpl 2003; 9:1174-1180.
50. Condron SL, Heneghan MA, Patel K, Dev A, McHutchinson JG, Muir AJ, et al. Predictors of death or retransplantation in patients with hepatitis C following liver transplantation [abstract]. Hepatology 2003;38(Suppl 1):534A.
51. Machicao VI, Bonatti H, Krishna M, Aqel BA, Lukens FJ, Nguyen JH, et al. Donor age affects fibrosis progression and graft survival after liver transplantation for hepatitis C. Transplantation 2004;77:84-92.
52. Wali MH, Heydtmann M, Harrison RF, Gunson BK, Mutimer DJ. Outcome of liver transplantation for patients infected by hepatitis C, including those infected by genotype 4. Liver Transpl 2003;9:796-804.
53. Brillanti S, Vivarelli M, De Ruvo N, Aden AA, Camaggi V, D'Errico A, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl 2002;8:884-888.
54. Burroughs AK. Induction immunosuppression for patients who underwent transplantation for cirrhosis caused by hepatitis C? The answer is no! Liver Transpl 2002;8(Suppl 1):S47-S49.
55. Fasola CG, Netto GJ, Onaca N, Thomas M, Sanchez EQ, Chinnakotla S, et al. A more severe hepatitis C recurrence (HCVR) post liver transplantation (OLT) observed in recent years may be explained by the use of lower dose corticosteroid (CS) maintenance protocols [abstract]. Hepatology 2003;38(Suppl 1):226A.
56. Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, et al. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-393.
57. Chopra KB, Demetris AJ, Blakolmer K, Dvorchik I, Laskus T, Wang LF, et al. Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. Transplantation 2003;76:1487-1491.
58. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-1243.
59. Charlton M, Ruppert K, Belle SH, Bass N, Schafer D, Wiesner RH, et al. Long-term results and modeling to predict outcomes in recipients with HCV infection: results of the NIDDK liver transplantation database. Liver Transpl 2004;10:1120-1130.
60. Busquets J, Xiol X, Figueras J, Jaurrieta E, Torras J, Ramos E, et al. The impact of donor age on liver transplantation: influence of donor age on early liver function and on subsequent patient and graft survival. Transplantation 2001;71:1765-1771.
61. Sebagh M, Rifai K, Feray C, Yilmaz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003;37:1293-1301.
62. Rifai K, Sebagh M, Karam V, Saliba F, Azoulay D, Adam R, et al. Donor age influences 10-year liver graft histology independently of hepatitis C virus infection. J Hepatol 2004;41:446-453.
63. Berenguer M, Aguilera V, Prieto M, Carrasco D, Rayon M, San Juan F, et al. Delayed onset of severe hepatitis C-related liver damage following liver transplantation: a matter of concern? Liver Transpl 2003;9:1152-1158.
64. Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan MF, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998;65: 1044-1046.
65. Ben Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. Transplant Proc 2003; 35:612-613.
66. Inoue K, Sekiyama K, Yamada M, Watanabe T, Yasuda H, Yoshiba M. Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial. J Gastroenterol 2003;38:567-572.
67. Nakagawa M, Sakamoto N, Enomoto N, Tanabe Y, Kanazawa N, Koyama T, et al. Specific inhibition of hepatitis C virus replication by cyclosporin A. Biochem Biophys Res Commun 2004;313:42-47.
68. Watashi K, Hijikata M, Hosaka M, Yamaji M, Shimotohno K. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-1288.
69. Hunt J, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, et al. Histological recurrence and progression of hepatitis C after orthotopic liver transplantation: influence of immunosuppressive regimens. Liver Transpl 2001;7:1056-1063.
70. Stangl JR, Carroll KL, Illichmann M, Striker R. Effect of anti-metabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004;77:562-567.